Group 1 - The company announced that its subsidiaries participated in a national centralized procurement process, with some products expected to be selected for procurement [1] - The procurement period for the selected products will last until December 31, 2028, and the company is unable to calculate the supply quantity at this time [1] - If the selected products are confirmed and contracts are signed, it will positively impact the company's sales, market share, and brand influence [2] Group 2 - The company approved a share repurchase plan on January 16, 2026, with a maximum repurchase price of 23.98 yuan per share and a minimum repurchase amount of 60 million yuan [6] - As of February 11, 2026, the company has repurchased a total of 6,856,400 shares, representing 0.65% of the total share capital, with a total expenditure of approximately 118.54 million yuan [7] - The repurchase will not significantly affect the company's operations, financial status, or future development, and the share distribution will still meet listing requirements [8]

Core Viewpoint - The company, through its subsidiaries, is participating in a national centralized procurement process for pharmaceuticals, which could enhance its market share and brand influence if selected products are confirmed and contracts are signed [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries and a controlling subsidiary are involved in the national centralized procurement for expiring drug agreements [1] - The procurement office announced the proposed selection results for the procurement on February 10, 2026 [1] Group 2: Potential Impact - If the proposed selected products are confirmed and contracts are signed, it will help the company expand sales of related products [1] - The successful procurement will ensure that medical institutions prioritize the selected drugs, which is expected to positively impact the company's future operating performance [1]